A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency

Trial Profile

A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs AG 348 (Primary)
  • Indications Haemolytic anaemia
  • Focus Adverse reactions; Proof of concept
  • Acronyms DRIVE PK
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 10 Dec 2017 According to an Agios Pharmaceuticals media release, Thirty-six of 43 patients who completed the six month core treatment period entered the extension period. As of the data cut-off, 29 patients remain on treatment in the extension period.
    • 10 Dec 2017 According to an Agios Pharmaceuticals media release, updated data from the study has been presented at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top